Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Key Highlights
- ➤Abbott launched commercial next-generation Oncodetect MRD test for solid-tumor patients
- ➤Whole-genome sequencing tracks up to 5,000 patient-specific variants
- ➤MAESTRO technology improves detection limit 30-fold to below one part per million
- ➤Test maintains >99% analytical specificity under high-end inputs
- ➤Modeling estimates more than 3 million U.S. solid-tumor patients could benefit
Expert Statements
Maimah Karmo, President of the Tigerlily Foundation
“New tools that give care teams more information about recurrence risk can support more meaningful conversations about what comes next.”
Dr. Rick Baehner, Divisional vice president, chief medical officer, precision oncology, Abbott's cancer diagnostics business
“MRD represents an important evolution in precision oncology, helping move cancer care beyond waiting for signs of recurrence toward more informed decisions throughout a patient’s care.”
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment PR Newswire
* Powered by whole-genome sequencing and MAESTRO(*) technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part per million under high-end inputs (1, 2, 3) * The next-generation Oncodetect test builds on more than 20 years of trusted leadership in using genomic information to personalize cancer care * Modeling estimates more than 3 million U.S. patients with solid tumors could potentially benefit from MRD testing(†) ABBOTT PARK, Ill., Oct. 26, 2026 /PRNewswire/ -- For many people with cancer, completing treatment can bring a new uncertainty: Is my cancer really gone?
Get started
Create a free account to read the full story.